- Home
- RZLT
RZLT
Rezolute Inc. (NV)
as 12-18-2024 1:42pm EST
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 292.0M | IPO Year: | N/A |
| Target Price: | $11.63 | AVG Volume (30 days): | 386.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.86 - $6.19 | Next Earning Date: | 02-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Rezolute Inc. (NV) (RZLT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hogenhuis Wladimir | RZLT | Director | Sep 24 '24 | Buy | $4.70 | 4,259 | $20,017.30 | 41,767 |
Latest Rezolute Inc. (NV) News
RZLT Breaking Stock News: Dive into RZLT Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
15 days ago
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Simply Wall St.
a month ago
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully
GlobeNewswire
a month ago
Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Rezolute to Participate in Upcoming Investor Conferences
Simply Wall St.
2 months ago
With 62% ownership, Rezolute, Inc. (NASDAQ:RZLT) boasts of strong institutional backing
GlobeNewswire
3 months ago
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
GlobeNewswire
3 months ago
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Compare RZLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RZLT Rezolute Inc. (NV) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.